Table 1.

Baseline characteristics of the 35 ALLGNHL21 patients who underwent TCR sequencing

	All (n = 35)	iPET− (n = 22)	iPET+ (n = 13)	P
Age, median (range)	56 (23–68)	59 (23–68)	52 (36–66)	0.3
Sex, n (%)
Male	27 (77%)	18 (82%)	9 (69%)	0.4
Female	8 (23%)	4 (18%)	4 (31%)
IPI a , n (%)
Low (0–1)	5 (15%)	2(10%)	3(23%)	0.2
Intermediate (2–3)	21 (64%)	12 (60%)	9 (69%)
High (4–5)	7 (21%)	6 (30%)	1 (8%)
Stage a , n (%)
Early (1–2)	5 (15%)	2 (10%)	3 (23%)	0.4
Advanced (3–4)	28 (85%)	18(90%)	10(77%)
COO a , n (%)
ABC	8 (35%)	5 (36%)	3 (33%)	0.3
GCB	12(52%)	6 (43%)	6 (67%)
UNC	3 (13%)	3 (21%)	0

ABC, activated B cell; COO, cell of origin; GCB, germinal B‐cell; IPI, International Prognostic Index; UNC, unclassified.

^aMissing or not available as follows: IPI (n = 2), stage (n = 2), COO (n = 12).